S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:SNY

Sanofi (SNY) Stock Forecast, Price & News

$54.02
-0.26 (-0.48%)
(As of 09/22/2023 ET)
Compare
Today's Range
$54.02
$54.44
50-Day Range
$50.95
$55.20
52-Week Range
$36.91
$57.82
Volume
948,416 shs
Average Volume
1.05 million shs
Market Capitalization
$136.39 billion
P/E Ratio
18.50
Dividend Yield
2.55%
Price Target
$60.00

Sanofi MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
11.1% Upside
$60.00 Price Target
Short Interest
Healthy
0.14% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.53mentions of Sanofi in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.78%
From $4.44 to $4.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

355th out of 965 stocks

Pharmaceutical Preparations Industry

156th out of 456 stocks


SNY stock logo

About Sanofi (NASDAQ:SNY) Stock

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Price History

SNY Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Sanofi: 3 Reasons For A Buy
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Why Sanofi (SNY) is a Top Value Stock for the Long-Term
Why Shares of MacroGenics Are Jumping Thursday
3 Pharma Stocks Investors Are Chasing for Value
See More Headlines
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Company Calendar

Last Earnings
7/28/2023
Today
9/24/2023
Next Earnings (Confirmed)
10/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNY
Employees
91,573
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$60.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+11.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$8.82 billion
Pretax Margin
25.40%

Debt

Sales & Book Value

Annual Sales
$45.31 billion
Cash Flow
$5.72 per share
Book Value
$31.40 per share

Miscellaneous

Outstanding Shares
2,524,780,000
Free Float
2,499,528,000
Market Cap
$136.39 billion
Optionable
Optionable
Beta
0.57

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Paul HudsonMr. Paul Hudson (Age 56)
    CEO & Director
    Comp: $4.08M
  • Mr. Jean-Baptiste Chasseloup de ChatillonMr. Jean-Baptiste Chasseloup de Chatillon (Age 58)
    Exec. VP & CFO
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and VP of Corp. Accounting
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 45)
    Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 66)
    Sr. VP of Global Diabetes and Sr. VP of Global Marketing
  • Ms. Natalie Bickford (Age 53)
    Exec. VP & Chief People Officer













SNY Stock - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNY shares.
View SNY analyst ratings
or view top-rated stocks.

What is Sanofi's stock price forecast for 2023?

7 brokerages have issued 12-month price objectives for Sanofi's shares. Their SNY share price forecasts range from $60.00 to $60.00. On average, they predict the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts price targets for SNY
or view top-rated stocks among Wall Street analysts.

How have SNY shares performed in 2023?

Sanofi's stock was trading at $48.43 at the beginning of 2023. Since then, SNY stock has increased by 11.5% and is now trading at $54.02.
View the best growth stocks for 2023 here
.

When is Sanofi's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our SNY earnings forecast
.

How can I listen to Sanofi's earnings call?

Sanofi will be holding an earnings conference call on Friday, October 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) posted its quarterly earnings data on Friday, July, 28th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.07. The business earned $10.85 billion during the quarter, compared to analysts' expectations of $11.47 billion. Sanofi had a net margin of 16.07% and a trailing twelve-month return on equity of 27.94%.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi declared an annual dividend on Tuesday, May 30th. Shareholders of record on Wednesday, May 31st will be given a dividend of $1.377 per share on Friday, June 23rd. This represents a yield of 2.94%. The ex-dividend date is Tuesday, May 30th.
Read our dividend analysis for SNY
.

Is Sanofi a good dividend stock?

Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 2.53%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 47.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 28.57% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

What is Sanofi's stock symbol?

Sanofi trades on the NASDAQ under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by many different institutional and retail investors. Top institutional investors include Boston Partners (0.52%), Fisher Asset Management LLC (0.51%), BlackRock Inc. (0.38%), Bank of New York Mellon Corp (0.30%), Camber Capital Management LP (0.16%) and Nuveen Asset Management LLC (0.12%).
View institutional ownership trends
.

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $54.02.

How much money does Sanofi make?

Sanofi (NASDAQ:SNY) has a market capitalization of $136.39 billion and generates $45.31 billion in revenue each year. The company earns $8.82 billion in net income (profit) each year or $2.92 on an earnings per share basis.

How many employees does Sanofi have?

The company employs 91,573 workers across the globe.

Does Sanofi have any subsidiaries?
The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The official website for the company is www.sanofi.com. The company can be reached via phone at (315) 377-4000, via email at ir@sanofi.com, or via fax at 33-1-53-77-43-03.

This page (NASDAQ:SNY) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -